{"id":39500,"date":"2026-08-03T10:10:36","date_gmt":"2026-08-03T08:10:36","guid":{"rendered":"https:\/\/ggba.swiss\/?p=39500"},"modified":"2026-08-03T10:10:37","modified_gmt":"2026-08-03T08:10:37","slug":"immitra-bio-raises-chf-2-4-million-to-advance-its-in-vivo-gene-editing-platform","status":"publish","type":"post","link":"https:\/\/ggba.swiss\/en\/immitra-bio-raises-chf-2-4-million-to-advance-its-in-vivo-gene-editing-platform\/","title":{"rendered":"Immitra Bio raises CHF 2.4 million to advance its in-vivo gene editing platform"},"content":{"rendered":"\n<p><a href=\"https:\/\/immitrabio.com\/\">Immitra Bio<\/a> has completed an upsized pre-seed financing round of CHF 2.4 million. CHF 2.25 million came from venture capital and private investors, with a further CHF 150,000 secured through non-dilutive funding. The round was led by Backbone Ventures and co-led by OCCIDENT, with participation from Another VC, Kickfund, Venture Kick, Z\u00fcrcher Kantonalbank, <a href=\"https:\/\/www.fongit.ch\/\">FONGIT<\/a>, the ETH Foundation and private investors.<\/p>\n\n\n\n<p>The company is developing a platform for one-time curative in-vivo gene editing therapies, combining a mutation-agnostic gene editing technology with a digital target identification platform. The approach is designed to avoid the complex ex-vivo cell manipulation, patient conditioning and stem cell transplantation required by current gene editing therapies, and to produce off-the-shelf formulations able to treat all patients with a given disease regardless of the underlying mutation.<\/p>\n\n\n\n<p>Proceeds will primarily support preclinical proof-of-concept studies for IB-003, the company&#8217;s lead candidate and a potential one-time curative treatment for an inherited anemia. The financing will also fund discovery and validation work across the company&#8217;s pipeline, enabled by its digital target discovery platform, as well as continued refinement of the platform itself.<\/p>\n","protected":false},"excerpt":{"rendered":"<p>Immitra Bio, based in Plan-les-Ouates in the canton of Geneva, has closed an upsized CHF 2.4 million pre-seed round to advance its scalable in-vivo gene editing platform and its lead candidate for an inherited anemia.<\/p>\n","protected":false},"author":6,"featured_media":39501,"comment_status":"closed","ping_status":"closed","sticky":false,"template":"","format":"standard","meta":{"_acf_changed":false,"inline_featured_image":false,"mc4wp_mailchimp_campaign":[],"footnotes":""},"categories":[833],"tags":[912,894,954,886],"class_list":["post-39500","post","type-post","status-publish","format-standard","has-post-thumbnail","hentry","category-life-science","tag-biotech","tag-financing","tag-gene-therapy","tag-rd"],"acf":[],"yoast_head":"<!-- This site is optimized with the Yoast SEO plugin v27.2 - https:\/\/yoast.com\/product\/yoast-seo-wordpress\/ -->\n<title>Immitra Bio raises CHF 2.4 million for in-vivo gene editing | GGBa<\/title>\n<meta name=\"description\" content=\"Geneva-based Immitra Bio has closed a CHF 2.4 million pre-seed round to advance its scalable in-vivo gene editing platform.\" \/>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/ggba.swiss\/en\/immitra-bio-raises-chf-2-4-million-to-advance-its-in-vivo-gene-editing-platform\/\" \/>\n<meta property=\"og:locale\" content=\"en_US\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"Immitra Bio raises CHF 2.4 million for in-vivo gene editing | GGBa\" \/>\n<meta property=\"og:description\" content=\"Geneva-based Immitra Bio has closed a CHF 2.4 million pre-seed round to advance its scalable in-vivo gene editing platform.\" \/>\n<meta property=\"og:url\" content=\"https:\/\/ggba.swiss\/en\/immitra-bio-raises-chf-2-4-million-to-advance-its-in-vivo-gene-editing-platform\/\" \/>\n<meta property=\"og:site_name\" content=\"Greater Geneva Bern area\" \/>\n<meta property=\"article:published_time\" content=\"2026-08-03T08:10:36+00:00\" \/>\n<meta property=\"article:modified_time\" content=\"2026-08-03T08:10:37+00:00\" \/>\n<meta property=\"og:image\" content=\"https:\/\/ggba.swiss\/app\/uploads\/2026\/08\/Immitra-Bio-Founders-1180x811-1.jpeg\" \/>\n\t<meta property=\"og:image:width\" content=\"1180\" \/>\n\t<meta property=\"og:image:height\" content=\"811\" \/>\n\t<meta property=\"og:image:type\" content=\"image\/jpeg\" \/>\n<meta name=\"author\" content=\"Pierre-Yves Oehrli\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:label1\" content=\"Written by\" \/>\n\t<meta name=\"twitter:data1\" content=\"Pierre-Yves Oehrli\" \/>\n\t<meta name=\"twitter:label2\" content=\"Est. reading time\" \/>\n\t<meta name=\"twitter:data2\" content=\"1 minute\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\/\/schema.org\",\"@graph\":[{\"@type\":\"Article\",\"@id\":\"https:\/\/ggba.swiss\/en\/immitra-bio-raises-chf-2-4-million-to-advance-its-in-vivo-gene-editing-platform\/#article\",\"isPartOf\":{\"@id\":\"https:\/\/ggba.swiss\/en\/immitra-bio-raises-chf-2-4-million-to-advance-its-in-vivo-gene-editing-platform\/\"},\"author\":{\"name\":\"Pierre-Yves Oehrli\",\"@id\":\"https:\/\/staging.ggba.swiss\/en\/#\/schema\/person\/0b2e6d04131e3d01237dcb741fa33d41\"},\"headline\":\"Immitra Bio raises CHF 2.4 million to advance its in-vivo gene editing platform\",\"datePublished\":\"2026-08-03T08:10:36+00:00\",\"dateModified\":\"2026-08-03T08:10:37+00:00\",\"mainEntityOfPage\":{\"@id\":\"https:\/\/ggba.swiss\/en\/immitra-bio-raises-chf-2-4-million-to-advance-its-in-vivo-gene-editing-platform\/\"},\"wordCount\":191,\"image\":{\"@id\":\"https:\/\/ggba.swiss\/en\/immitra-bio-raises-chf-2-4-million-to-advance-its-in-vivo-gene-editing-platform\/#primaryimage\"},\"thumbnailUrl\":\"https:\/\/ggba.swiss\/app\/uploads\/2026\/08\/Immitra-Bio-Founders-1180x811-1.jpeg\",\"keywords\":[\"Biotech\",\"Financing\",\"Gene Therapy\",\"R&amp;D\"],\"articleSection\":[\"Life sciences\"],\"inLanguage\":\"en-US\"},{\"@type\":\"WebPage\",\"@id\":\"https:\/\/ggba.swiss\/en\/immitra-bio-raises-chf-2-4-million-to-advance-its-in-vivo-gene-editing-platform\/\",\"url\":\"https:\/\/ggba.swiss\/en\/immitra-bio-raises-chf-2-4-million-to-advance-its-in-vivo-gene-editing-platform\/\",\"name\":\"Immitra Bio raises CHF 2.4 million for in-vivo gene editing | GGBa\",\"isPartOf\":{\"@id\":\"https:\/\/staging.ggba.swiss\/en\/#website\"},\"primaryImageOfPage\":{\"@id\":\"https:\/\/ggba.swiss\/en\/immitra-bio-raises-chf-2-4-million-to-advance-its-in-vivo-gene-editing-platform\/#primaryimage\"},\"image\":{\"@id\":\"https:\/\/ggba.swiss\/en\/immitra-bio-raises-chf-2-4-million-to-advance-its-in-vivo-gene-editing-platform\/#primaryimage\"},\"thumbnailUrl\":\"https:\/\/ggba.swiss\/app\/uploads\/2026\/08\/Immitra-Bio-Founders-1180x811-1.jpeg\",\"datePublished\":\"2026-08-03T08:10:36+00:00\",\"dateModified\":\"2026-08-03T08:10:37+00:00\",\"author\":{\"@id\":\"https:\/\/staging.ggba.swiss\/en\/#\/schema\/person\/0b2e6d04131e3d01237dcb741fa33d41\"},\"description\":\"Geneva-based Immitra Bio has closed a CHF 2.4 million pre-seed round to advance its scalable in-vivo gene editing platform.\",\"breadcrumb\":{\"@id\":\"https:\/\/ggba.swiss\/en\/immitra-bio-raises-chf-2-4-million-to-advance-its-in-vivo-gene-editing-platform\/#breadcrumb\"},\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\/\/ggba.swiss\/en\/immitra-bio-raises-chf-2-4-million-to-advance-its-in-vivo-gene-editing-platform\/\"]}]},{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\/\/ggba.swiss\/en\/immitra-bio-raises-chf-2-4-million-to-advance-its-in-vivo-gene-editing-platform\/#primaryimage\",\"url\":\"https:\/\/ggba.swiss\/app\/uploads\/2026\/08\/Immitra-Bio-Founders-1180x811-1.jpeg\",\"contentUrl\":\"https:\/\/ggba.swiss\/app\/uploads\/2026\/08\/Immitra-Bio-Founders-1180x811-1.jpeg\",\"width\":1180,\"height\":811,\"caption\":\"The team at Immitra Bio develops in-vivo gene editing therapies designed as off-the-shelf treatments that work regardless of a patient's underlying mutation. | \u00a9 Immitra Bio\"},{\"@type\":\"BreadcrumbList\",\"@id\":\"https:\/\/ggba.swiss\/en\/immitra-bio-raises-chf-2-4-million-to-advance-its-in-vivo-gene-editing-platform\/#breadcrumb\",\"itemListElement\":[{\"@type\":\"ListItem\",\"position\":1,\"name\":\"Home\",\"item\":\"https:\/\/ggba.swiss\/en\/\"},{\"@type\":\"ListItem\",\"position\":2,\"name\":\"Immitra Bio raises CHF 2.4 million to advance its in-vivo gene editing platform\"}]},{\"@type\":\"WebSite\",\"@id\":\"https:\/\/staging.ggba.swiss\/en\/#website\",\"url\":\"https:\/\/staging.ggba.swiss\/en\/\",\"name\":\"Greater Geneva Bern area\",\"description\":\"\",\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\/\/staging.ggba.swiss\/en\/?s={search_term_string}\"},\"query-input\":{\"@type\":\"PropertyValueSpecification\",\"valueRequired\":true,\"valueName\":\"search_term_string\"}}],\"inLanguage\":\"en-US\"},{\"@type\":\"Person\",\"@id\":\"https:\/\/staging.ggba.swiss\/en\/#\/schema\/person\/0b2e6d04131e3d01237dcb741fa33d41\",\"name\":\"Pierre-Yves Oehrli\",\"url\":\"https:\/\/ggba.swiss\/en\/author\/pierre-yves-oehrli\/\"}]}<\/script>\n<!-- \/ Yoast SEO plugin. -->","yoast_head_json":{"title":"Immitra Bio raises CHF 2.4 million for in-vivo gene editing | GGBa","description":"Geneva-based Immitra Bio has closed a CHF 2.4 million pre-seed round to advance its scalable in-vivo gene editing platform.","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/ggba.swiss\/en\/immitra-bio-raises-chf-2-4-million-to-advance-its-in-vivo-gene-editing-platform\/","og_locale":"en_US","og_type":"article","og_title":"Immitra Bio raises CHF 2.4 million for in-vivo gene editing | GGBa","og_description":"Geneva-based Immitra Bio has closed a CHF 2.4 million pre-seed round to advance its scalable in-vivo gene editing platform.","og_url":"https:\/\/ggba.swiss\/en\/immitra-bio-raises-chf-2-4-million-to-advance-its-in-vivo-gene-editing-platform\/","og_site_name":"Greater Geneva Bern area","article_published_time":"2026-08-03T08:10:36+00:00","article_modified_time":"2026-08-03T08:10:37+00:00","og_image":[{"width":1180,"height":811,"url":"https:\/\/ggba.swiss\/app\/uploads\/2026\/08\/Immitra-Bio-Founders-1180x811-1.jpeg","type":"image\/jpeg"}],"author":"Pierre-Yves Oehrli","twitter_card":"summary_large_image","twitter_misc":{"Written by":"Pierre-Yves Oehrli","Est. reading time":"1 minute"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"Article","@id":"https:\/\/ggba.swiss\/en\/immitra-bio-raises-chf-2-4-million-to-advance-its-in-vivo-gene-editing-platform\/#article","isPartOf":{"@id":"https:\/\/ggba.swiss\/en\/immitra-bio-raises-chf-2-4-million-to-advance-its-in-vivo-gene-editing-platform\/"},"author":{"name":"Pierre-Yves Oehrli","@id":"https:\/\/staging.ggba.swiss\/en\/#\/schema\/person\/0b2e6d04131e3d01237dcb741fa33d41"},"headline":"Immitra Bio raises CHF 2.4 million to advance its in-vivo gene editing platform","datePublished":"2026-08-03T08:10:36+00:00","dateModified":"2026-08-03T08:10:37+00:00","mainEntityOfPage":{"@id":"https:\/\/ggba.swiss\/en\/immitra-bio-raises-chf-2-4-million-to-advance-its-in-vivo-gene-editing-platform\/"},"wordCount":191,"image":{"@id":"https:\/\/ggba.swiss\/en\/immitra-bio-raises-chf-2-4-million-to-advance-its-in-vivo-gene-editing-platform\/#primaryimage"},"thumbnailUrl":"https:\/\/ggba.swiss\/app\/uploads\/2026\/08\/Immitra-Bio-Founders-1180x811-1.jpeg","keywords":["Biotech","Financing","Gene Therapy","R&amp;D"],"articleSection":["Life sciences"],"inLanguage":"en-US"},{"@type":"WebPage","@id":"https:\/\/ggba.swiss\/en\/immitra-bio-raises-chf-2-4-million-to-advance-its-in-vivo-gene-editing-platform\/","url":"https:\/\/ggba.swiss\/en\/immitra-bio-raises-chf-2-4-million-to-advance-its-in-vivo-gene-editing-platform\/","name":"Immitra Bio raises CHF 2.4 million for in-vivo gene editing | GGBa","isPartOf":{"@id":"https:\/\/staging.ggba.swiss\/en\/#website"},"primaryImageOfPage":{"@id":"https:\/\/ggba.swiss\/en\/immitra-bio-raises-chf-2-4-million-to-advance-its-in-vivo-gene-editing-platform\/#primaryimage"},"image":{"@id":"https:\/\/ggba.swiss\/en\/immitra-bio-raises-chf-2-4-million-to-advance-its-in-vivo-gene-editing-platform\/#primaryimage"},"thumbnailUrl":"https:\/\/ggba.swiss\/app\/uploads\/2026\/08\/Immitra-Bio-Founders-1180x811-1.jpeg","datePublished":"2026-08-03T08:10:36+00:00","dateModified":"2026-08-03T08:10:37+00:00","author":{"@id":"https:\/\/staging.ggba.swiss\/en\/#\/schema\/person\/0b2e6d04131e3d01237dcb741fa33d41"},"description":"Geneva-based Immitra Bio has closed a CHF 2.4 million pre-seed round to advance its scalable in-vivo gene editing platform.","breadcrumb":{"@id":"https:\/\/ggba.swiss\/en\/immitra-bio-raises-chf-2-4-million-to-advance-its-in-vivo-gene-editing-platform\/#breadcrumb"},"inLanguage":"en-US","potentialAction":[{"@type":"ReadAction","target":["https:\/\/ggba.swiss\/en\/immitra-bio-raises-chf-2-4-million-to-advance-its-in-vivo-gene-editing-platform\/"]}]},{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/ggba.swiss\/en\/immitra-bio-raises-chf-2-4-million-to-advance-its-in-vivo-gene-editing-platform\/#primaryimage","url":"https:\/\/ggba.swiss\/app\/uploads\/2026\/08\/Immitra-Bio-Founders-1180x811-1.jpeg","contentUrl":"https:\/\/ggba.swiss\/app\/uploads\/2026\/08\/Immitra-Bio-Founders-1180x811-1.jpeg","width":1180,"height":811,"caption":"The team at Immitra Bio develops in-vivo gene editing therapies designed as off-the-shelf treatments that work regardless of a patient's underlying mutation. | \u00a9 Immitra Bio"},{"@type":"BreadcrumbList","@id":"https:\/\/ggba.swiss\/en\/immitra-bio-raises-chf-2-4-million-to-advance-its-in-vivo-gene-editing-platform\/#breadcrumb","itemListElement":[{"@type":"ListItem","position":1,"name":"Home","item":"https:\/\/ggba.swiss\/en\/"},{"@type":"ListItem","position":2,"name":"Immitra Bio raises CHF 2.4 million to advance its in-vivo gene editing platform"}]},{"@type":"WebSite","@id":"https:\/\/staging.ggba.swiss\/en\/#website","url":"https:\/\/staging.ggba.swiss\/en\/","name":"Greater Geneva Bern area","description":"","potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/staging.ggba.swiss\/en\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"en-US"},{"@type":"Person","@id":"https:\/\/staging.ggba.swiss\/en\/#\/schema\/person\/0b2e6d04131e3d01237dcb741fa33d41","name":"Pierre-Yves Oehrli","url":"https:\/\/ggba.swiss\/en\/author\/pierre-yves-oehrli\/"}]}},"_links":{"self":[{"href":"https:\/\/ggba.swiss\/en\/wp-json\/wp\/v2\/posts\/39500","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/ggba.swiss\/en\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/ggba.swiss\/en\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/ggba.swiss\/en\/wp-json\/wp\/v2\/users\/6"}],"replies":[{"embeddable":true,"href":"https:\/\/ggba.swiss\/en\/wp-json\/wp\/v2\/comments?post=39500"}],"version-history":[{"count":1,"href":"https:\/\/ggba.swiss\/en\/wp-json\/wp\/v2\/posts\/39500\/revisions"}],"predecessor-version":[{"id":39504,"href":"https:\/\/ggba.swiss\/en\/wp-json\/wp\/v2\/posts\/39500\/revisions\/39504"}],"wp:featuredmedia":[{"embeddable":true,"href":"https:\/\/ggba.swiss\/en\/wp-json\/wp\/v2\/media\/39501"}],"wp:attachment":[{"href":"https:\/\/ggba.swiss\/en\/wp-json\/wp\/v2\/media?parent=39500"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/ggba.swiss\/en\/wp-json\/wp\/v2\/categories?post=39500"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/ggba.swiss\/en\/wp-json\/wp\/v2\/tags?post=39500"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}